tiprankstipranks
Trending News
More News >
Cytori Cell Research Institute, Inc. (JP:3750)
:3750
Japanese Market
Advertisement

Cytori Cell Research Institute, Inc. (3750) AI Stock Analysis

Compare
0 Followers

Top Page

JP:3750

Cytori Cell Research Institute, Inc.

(3750)

Rating:54Neutral
Price Target:
¥827.00
▼(-9.12%Downside)
Cytori Cell Research Institute's score is primarily driven by its weak financial performance, reflecting significant profitability and liquidity challenges, along with a concerning valuation due to negative earnings. Despite these issues, the stock's strong technical indicators suggest short-term bullish momentum, which partially offsets the financial weaknesses. The absence of earnings call insights and corporate events further underscores the need for financial improvement.

Cytori Cell Research Institute, Inc. (3750) vs. iShares MSCI Japan ETF (EWJ)

Cytori Cell Research Institute, Inc. Business Overview & Revenue Model

Company DescriptionCytori Cell Research Institute, Inc. (3750) is a biotechnology company focused on the development and commercialization of regenerative medicine therapies. The company specializes in cell-based treatments, leveraging proprietary technology to harness the potential of regenerative cells for medical applications. Its core products and services revolve around providing innovative solutions for a range of conditions by utilizing advanced cellular research and therapies.
How the Company Makes MoneyCytori Cell Research Institute, Inc. generates revenue primarily through the development and commercialization of its proprietary cell-based therapies. The company earns income by selling its regenerative medicine products and licensing its technology to other biotechnology and pharmaceutical companies. Additionally, it may engage in strategic partnerships and collaborations with research institutions or healthcare providers to expand its market reach and enhance its product offerings. Revenue streams can also include grants and funding from government or private entities supporting scientific research and development in regenerative medicine.

Cytori Cell Research Institute, Inc. Financial Statement Overview

Summary
Cytori Cell Research Institute faces significant financial challenges. The income statement shows declining revenues and increasing losses, compounded by high financial leverage and negative cash flow from operations. These factors indicate a high financial risk and necessitate strategic revenue stabilization and cost management.
Income Statement
25
Negative
Cytori Cell Research Institute's income statement reveals significant challenges, as evidenced by declining revenue and profitability. The revenue has decreased considerably from previous years, and the gross profit has turned negative, indicating increased cost pressures. The net profit margin and EBIT margin are both negative, reflecting persistent losses. The revenue growth rate has been negative for the latest period, showing a decline in sales. These factors contribute to a low score, highlighting the need for revenue stabilization and cost management strategies.
Balance Sheet
35
Negative
The balance sheet indicates a precarious financial position with high leverage. The debt-to-equity ratio is substantial, suggesting heavy reliance on debt financing, which poses a risk given the industry volatility. However, despite the challenges, a moderate equity ratio shows that the company retains some level of equity relative to its assets. The return on equity is negative due to losses incurred, further emphasizing financial instability. Overall, the balance sheet reflects high financial risk, warranting cautious management.
Cash Flow
20
Very Negative
The cash flow statement presents concerning trends. The operating cash flow is negative, indicating core operations are not generating cash, and free cash flow has also decreased, showing challenges in maintaining liquidity. The free cash flow growth rate is negative, further exacerbating the liquidity concerns. The ratio of operating cash flow to net income is unfavorable, reflecting operational inefficiencies. These cash flow issues highlight the need for improved cash management and operational efficiency.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue263.80M122.20M1.56B2.14B1.34B1.39B
Gross Profit129.64M-55.56M1.29B1.27B859.23M760.32M
EBITDA-906.82M-2.02B-603.09M-705.34M348.90M-261.86M
Net Income-60.21M-2.14B138.16M-1.06B-77.63M-831.86M
Balance Sheet
Total Assets4.89B3.54B5.82B14.09B16.01B14.92B
Cash, Cash Equivalents and Short-Term Investments443.00M255.98M1.04B1.12B851.56M1.07B
Total Debt2.66B2.65B2.47B8.51B9.27B8.53B
Total Liabilities2.87B2.91B3.02B11.43B12.29B11.38B
Stockholders Equity2.02B630.54M2.79B2.65B3.71B3.55B
Cash Flow
Free Cash Flow0.00-995.12M-1.17B-198.04M-367.83M-98.86M
Operating Cash Flow0.00-987.04M-1.15B-39.52M-187.78M-82.90M
Investing Cash Flow0.0018.13M8.69B-283.06M-216.19M6.70M
Financing Cash Flow0.00176.43M-7.17B294.23M35.80M150.65M

Cytori Cell Research Institute, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price910.00
Price Trends
50DMA
780.38
Positive
100DMA
779.15
Positive
200DMA
825.22
Positive
Market Momentum
MACD
38.21
Positive
RSI
64.69
Neutral
STOCH
50.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3750, the sentiment is Positive. The current price of 910 is above the 20-day moving average (MA) of 885.25, above the 50-day MA of 780.38, and above the 200-day MA of 825.22, indicating a bullish trend. The MACD of 38.21 indicates Positive momentum. The RSI at 64.69 is Neutral, neither overbought nor oversold. The STOCH value of 50.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3750.

Cytori Cell Research Institute, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥355.44B11.35-2.99%2.49%11.76%-10.21%
54
Neutral
¥8.03B55.07
-92.17%-1648.96%
54
Neutral
¥3.57B
12.66%24.73%
47
Neutral
¥8.83B-148.36%22.93%47.73%
42
Neutral
€5.44B-113.58%4.59%9.71%
37
Underperform
¥4.28B
-96.64%8.92%
28
Underperform
¥8.64B
-11.46%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3750
Cytori Cell Research Institute, Inc.
899.00
-44.00
-4.67%
JP:4591
Ribomic, Inc.
112.00
14.00
14.29%
JP:4598
Delta-Fly Pharma, Inc.
715.00
109.00
17.99%
JP:4884
Kringle Pharma, Inc.
512.00
-473.00
-48.02%
JP:4576
D.Western Therapeutics Institute
117.00
27.00
30.00%
JP:4564
OncoTherapy Science
29.00
-14.00
-32.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 01, 2025